

Cleaved-Factor XIIIa (G39) Polyclonal Antibody

Description

Product type	Primary Antibody
Code	BT-AP01927
Host	Rabbit
Isotype	IgG
Size	20ul, 50ul, 100ul
Immunogen	The antiserum was produced against synthesized peptide derived from human FA13A. AA range:20-69
Mol wt	83267
Species reactivity	Human
Clonality	Polyclonal
Recommended application	WB, ELISA
Concentration	1 mg/ml
Full name	Cleaved-Factor XIIIa (G39) Antibody
Synonyms	F13A1; F13A; Coagulation factor XIII A chain; Coagulation factor XIIIa; Protein-glutamine gamma- glutamyltransferase A chain; Transglutaminase A chain

This product is for research use only, not for use in human, therapeutic or diagnostic procedure.


Background

F13A1 encodes the coagulation factor XIII A subunit. Coagulation factor XIII is the last zymogen to become activated in the blood coagulation cascade. Plasma factor XIII is a heterotetramer composed of 2 A subunits and 2 B subunits. The A subunits have catalytic function, and the B subunits do not have enzymatic activity and may serve as plasma carrier molecules. Platelet factor XIII is comprised only of 2 A subunits, which are identical to those of plasma origin. Upon cleavage of the activation peptide by thrombin and in the presence of calcium ion, the plasma factor XIII dissociates its B subunits and yields the same active enzyme, factor XIIIa, as platelet factor XIII. This enzyme acts as a transglutaminase to catalyze the formation of gamma-glutamyl-epsilon-lysine crosslinking between fibrin molecules, thus stabilizing the fibrin clot. It also crosslinks alpha-2-plasmin inhibitor, or fibronectin, to the alpha chains of fibrin. Factor XIII deficiency is classified into two categories: type I deficiency, characterized by the lack of both the A and B subunits; and type II deficiency, characterized by the lack of the A subunit alone. These defects can result in a lifelong bleeding tendency, defective wound healing, and habitual abortion.

Recommended Dilution

WB: 1: 500 - 1: 2000 ELISA: 1: 20000 Not yet tested in other applications.

Images



Western blot analysis of lysates from Jurkat cells, treated with etoposide 25uM 24h, using FA13A (Cleaved-Gly39) Antibody. The lane on the right is blocked with the synthesized peptide.

501 Changsheng S Rd, Nanhu Dist, Jiaxing, Zhejiang, China

Tel: 86 21 31007137 | E-mail: save@bt-laboratory.com | www.bt-laboratory.com